Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | SOX18 | P35713 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9062915 | 0.93 | HDAC1 (0.68) | CYP1A2HDAC1HDAC8CYP2D6CYP2C19 | |
| SCHEMBL19612760 | 0.93 | HDAC1 (0.68) | CYP1A2HDAC1HDAC8CYP2D6CYP2C19 | |
| SCHEMBL7191582 | 0.89 | CYP1A2 (0.62) | CYP1A2HDAC1HDAC8CYP2D6CYP2C19 | |
| SCHEMBL30061865 | 0.84 | CYP1A2 (1.00) | CYP1A2HDAC1HDAC8CYP2D6CYP2C19 | |
| SCHEMBL1285452 | 0.84 | CYP1A2 (0.75) | CYP1A2HDAC1HDAC8CYP2D6CYP2C19 | |
| SCHEMBL2318140 | 0.84 | CYP1A2 (1.00) | CYP1A2HDAC1HDAC8CYP2D6CYP2C19 | |
| SCHEMBL5182845 | 0.83 | CYP1A2 (0.73) | CYP1A2HDAC1HDAC8CYP2D6CYP2C19 | |
| Water SCHEMBL27348665 | 0.83 | CYP1A2 (0.73) | CYP1A2HDAC1HDAC8CYP2D6CYP2C19 | |
| SCHEMBL22190341 | 0.80 | HDAC1 (0.88) | CYP1A2HDAC1HDAC8HCAR2HDAC3 | |
| SCHEMBL30060248 | 0.80 | HDAC1 (0.88) | CYP1A2HDAC1HDAC8HCAR2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200095217-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-03-26 | — | — | US | disclosed |
| US-10450288-B2 | Hydroxy formamide derivatives and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-20160340328-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-11-24 | — | — | US | disclosed |
| EP-3092233-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015104684-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095217-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | BMP1, BMPR1A, BMPR2 | CYP1A2 1422/4885HDAC1 243/4885HDAC8 537/4885 |
| US-20160340328-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | BMP1, BMPR1A, BMPR2 | CYP1A2 1422/4885HDAC1 243/4885HDAC8 537/4885 |
| US-10450288-B2 | Hydroxy formamide derivatives and their use | BMP1, BMPR1A, BMPR2 | CYP1A2 1422/4885HDAC1 243/4885HDAC8 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.